Ignite Creation Date:
2025-12-25 @ 5:04 AM
Ignite Modification Date:
2026-03-09 @ 4:10 AM
Study NCT ID:
NCT01711918
Status:
COMPLETED
Last Update Posted:
2018-02-09
First Post:
2012-10-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Sponsor:
Ron Schey
Organization:
Study Overview
Official Title:
Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis
Status:
COMPLETED
Status Verified Date:
2018-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To provide oral domperidone to patients between the ages of 18 and 60 years of age, according to the investigator's judgment, a prokinetic effect is needed for the relief of severe gastroparesis. We have defined severe gastroparesis as 1) positive gastric emptying scintigraphy (more than 10% residue at 4 hours), 2) nausea, 3) early satiety, 4) abdominal pain. We will recruit patients for two years and the patients will be given domperidone for up to two years.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: